Holen Sie sich die Stockscreener-App
14.25
0.14%
-0.02
Schlusskurs vom Vortag:
$14.27
Offen:
$14.5
24-Stunden-Volumen:
101.60K
Relative Volume:
2.77
Marktkapitalisierung:
$127.79M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-40.62M
KGV:
-0.7342
EPS:
-19.4076
Netto-Cashflow:
$-35.63M
1W Leistung:
+6.74%
1M Leistung:
+39.71%
6M Leistung:
+75.28%
1J Leistung:
+41.61%
1-Tages-Spanne:
$13.90
$14.75
1-Wochen-Bereich:
$13.41
$15.00
52-Wochen-Spanne:
$6.27
$39.75
Promis Neurosciences Inc Stock (PMN) Company Profile
Firmenname
Promis Neurosciences Inc
Sektor
Branche
Telefon
416-847-6898
Adresse
SUITE 200, 1920 YONGE STREET, TORONTO
Compare PMN vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PMN
Promis Neurosciences Inc
|
14.25 | 127.79M | 0 | -40.62M | -35.63M | -19.41 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Promis Neurosciences Inc Aktie (PMN) Neueste Nachrichten
ProMIS Neurosciences Inc. Financial Statements – NASDAQ:PMN - TradingView
ProMIS Neurosciences (PMN) Slips Marginally, Holds Near Key SupportTick Index - dars.gov.et
PMN Initiated Coverage by Cantor Fitzgerald -- Rating Set to Ove - GuruFocus
Wall Street Analysts See a 230.23% Upside in Promis Neurosciences (PMN): Can the Stock Really Move This High? - Yahoo Finance
ProMIS Neurosciences Inc (PMN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Enterprise value to revenue forward of ProMIS Neurosciences Inc. – NASDAQ:PMN - TradingView
ProMIS Neurosciences Inc. Actuals & Estimates (NASDAQ:PMN) - TradingView
PMN Forecast — Price Target — Prediction for 2027 - TradingView
Price to earnings forward of ProMIS Neurosciences Inc. – NASDAQ:PMN - TradingView
H.C. Wainwright Maintains ProMIS Neurosciences(PMN.US) With Buy Rating, Maintains Target Price $18 - Moomoo
Price to sales forward of ProMIS Neurosciences Inc. – NASDAQ:PMN - TradingView
Price to book forward of ProMIS Neurosciences Inc. – NASDAQ:PMN - TradingView
PMN Reiterated by HC Wainwright & Co. -- Price Target Maintained at $18 - GuruFocus
H.C. Wainwright reiterates ProMIS Neurosciences stock rating at buy By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates ProMIS Neurosciences stock rating at buy - Investing.com
ProMIS Neurosciences Inc (PMN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
ProMIS Neurosciences Inc (PMN) Institutional Confidence - TradingKey
ProMIS Neurosciences Inc (PMN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
ProMIS Neurosciences Inc (PMN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
ProMIS Neurosciences Inc (PMN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
ProMIS Neurosciences Inc (PMN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ProMIS Neurosciences Inc (PMN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
ProMIS Neurosciences Inc (PMN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
PMN Q1 2026 Earnings: EPS Beat Surprises as ProMIS Advances PipelinePretax Income Report - newsline.com
PMN Q1 2026 Earnings: Narrowing Losses Amidst Clinical ProgressProfit Inflection Point - newsline.com
ProMIS Neurosciences (PMN) Dips 3.54% as Biotech Stock Tests Key Support ZonePrice Action Signals - newsline.com
All You Need to Know About Promis Neurosciences (PMN) Rating Upgrade to Buy - Yahoo Finance
Wall Street Analysts Think Promis Neurosciences (PMN) Could Surge 231.78%: Read This Before Placing a Bet - Yahoo Finance
ProMIS Neurosciences Inc. (PMN) Q1 2026 Earnings: Narrower-Than-Expected Loss Signals Cost Discipline Amid Pipeline AdvancesAnalyst Drop Coverage - newsline.com
H.C. Wainwright reiterates Buy on ProMIS Neurosciences stock By Investing.com - Investing.com Canada
PMN Q1 2026 Earnings: Narrower-than-Expected Loss Amid Ongoing Clinical DevelopmentROA Comparison - newsline.com
ProMIS Neurosciences Inc Annual Shareholders Meeting Transcript - GuruFocus
PMN Q1 2026 Earnings: EPS Surprises to the Upside Despite Lack of RevenueMargin Guidance - newsline.com
ProMIS Neurosciences (PMN) Slips 3.3% as Biotech Sentiment Shifts – Key Support Holds at $9.56Last Point Resistance - dars.gov.et
ProMIS Neurosciences (PMN) Faces Bearish Pressure as Shares Slide 3.70%Anchored VWAP - dars.gov.et
ProMIS Neurosciences (PMN) Holds Steady Near Support as Biotech Sector Watches Key LevelsSynthetic Short - newsline.com
ProMIS Neurosciences to Participate in Upcoming Conferences in June - The Manila Times
Alzheimer’s drug trial data from ProMIS expected in early Q3 2026 - Stock Titan
PMN Technical Analysis | Trend, Signals & Chart Patterns | PROMIS NEUROSCIENCES INC (NASDAQ:PMN) - ChartMill
PMNProMIS Neurosciences Inc Stock Price and Quote - Finviz
ProMIS Neurosciences (PMN) Slips 5.65% as Shares Test Key Support LevelWave Alternation - newsline.com
PMN Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Progress in Neurodegenerative PipelineRevenue Breakdown Analysis - The Legal Advocate
PMN Q1 2026 Earnings: Narrower-than-expected Loss; Stock Gains on Pipeline ProgressPretax Income Report - Newser
Yu Fan's ProMIS Neurosciences Inc(PMN) Holding History - GuruFocus
ProMIS Neurosciences (PMN) director granted 16,500 options at $10.77 strike price - Stock Titan
ProMIS Neurosciences (PMN) director granted options on 16,500 shares - Stock Titan
ProMIS Neurosciences (PMN) CEO awarded 160,000 options at $10.77 strike - Stock Titan
ProMIS Neurosciences (PMN) director awarded long-dated stock options - Stock Titan
ProMIS Neurosciences (PMN) awards CSO 50,000 options vesting over 4 years - Stock Titan
Executive at ProMIS (PMN) receives 18,167 stock options expiring 2036 - Stock Titan
ProMIS Neurosciences (PMN) director receives 16,500 stock options grant - Stock Titan
Finanzdaten der Promis Neurosciences Inc-Aktie (PMN)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.64%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):